个人简介
1985年毕业于福建医科大学医疗系获学士学位，1991年毕业于福建医科大学获肿瘤药理学专业硕士学位，1999年毕业于中科院上海药物研究所获分子肿瘤药理学专业博士学位。1999-2002年在美国田纳西大学和St. Jude儿童研究医院从事博士后研究工作。2002年加入中科院上海药物研究所国家新药重点研究室肿瘤药理组研究员。2006年加入亚盛医药研发有限公司任生物部总监。2007年加入罗氏研发中心（中国），先后任物筛选技术部主任、分子肿瘤部主任、体内药理学部主任等职。2013年加入华东师范大学。国家药品监督管理局（SFDA）药品审评中心审评专家、中国药理学会肿瘤药理与化疗专业委员会委员。在高质量杂志上发表研究文章94篇，综述14篇，9部专著部分章节的编撰，合作申请32项专利（17项授权）。先后主持多项国家科技部863和973课题及国家自然科学基金项目。参与发明一个1.1类新药进入临床，领导完成数个抗肿瘤新药临床前研发的完整过程，并领导参与新药临床I/IIa期实验。
教育经历
1980-1985 医学士 专业：医疗系 福建医科大学
1988-1991 硕士 专业：肿瘤药理学 福建医科大学
1996-1999 博士 专业：分子肿瘤药理学 中国科学院上海药物研究所
1999-2000 博士后 专业：分子肿瘤药理学 美国田纳西州立大学医学院基因治疗实验室
2000-2002 博士后 专业：分子肿瘤药理学 美国St. Jude儿童研究医院分子药理学室
工作经历
中国科学院上海药物研究所肿瘤药理室
1985-1988 助教，福建医科大学生理室
1988-1991 硕士生 福建医科大学药理室
1991-1996 讲师、室副主任，福建医科大学药理室
1996-1999 博士生，中国科学院上海药物研究所肿瘤药理室
1999-2000 博士后，美国田纳西州立大学医学院基因治疗实验室
2000-2002 博士后，美国St. Jude儿童研究医院分子药理学室
2002-2006 副研究员、研究员，中科院上海药物研究所，国家新药重点研究室肿瘤药理组
2006-2007 生物部总监，江苏亚盛医药开发有限公司
2007-2012 药物筛选技术部主任、分子肿瘤部主任、体内药理学部主任，罗氏研发（中国）有限公司
2013.2-今 药理学教授/博导、中心副主任，华东师范大学，化学与分子工程学院，上海市分子治疗与新药创制工程研究中心
研究领域
从事分子肿瘤药理学及分子靶向抗肿瘤新药研发。
1. 抗肿瘤恶病质新药研发
2. 肿瘤多药耐药逆转剂新药研发
3. 小分子激酶抑制剂抗肿瘤新药研发
4. 双/多靶点抗肿瘤新药研发
近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis 1 of IL-6 and tumor derived extracellular vesicles. J Cachexia Sarcopenia Muscle 2022; in press. (IF 12.91)
miR-126-5p affects the chemosensitivity of colorectal cancer cells 1 by targeting SPRED1, ERK1/2 pathway and apoptosis. Genes & Diseases 2022; Online. (IF 7.103)
The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo. Oncogene 2022 Feb; 41(7):1050-1062. (IF 9.867)
Exosomes derived from colon cancer containing GDF15 promote muscle atrophy via Bcl-2/caspase-3 pathway. Cell Death Discovery. 2022 Apr; 8:162. (IF 5.24)
Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway. Phytomedicine 2021 Nov; 95:153858. (IF 5.34)
Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J Cachexia Sarcopenia Muscle 2021; 12:1553-1569. (IF 12.91)
miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. Cancers. 2021 July; 13: 3323. (IF 6.639)
Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle 2021 Jun;12(3):779-795. (IF 12.91)
Cancer-Derived Exosomes miRNAs Induce Skeletal Muscle Wasting by Bcl-2Mediated Apoptosis in Colon Cancer Cachexia. Mol Ther Nucleic Acids 2021 June; 24: 923-938. (IF 8.886)
Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res 2021 Apr; 11(4):1428-1445. (IF 6.166)
Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis. Mol Ther Nucleic Acids 2020 Jun 1; 21:229-241. (IF 8.886)
Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I. Acta Pharmacol Sin. 2020; 41(2):237-248. (IF 6.15)
NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3. Am J Cancer Res 2019; 9(11):2364-2378. (IF 6.166)
L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo. Front Pharmacol 2019; 10:89. (IF 5.81)
SiBaoChongCao exhibited anti-fatigue activities and ameliorated cancer cachexia in mice. RSC Adv. 2019 Jun; 9: 17440-56. (IF 3.361)
Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis. Eur J Med Chem 2018; 150:757-770. (IF 6.514)
ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo. Pharmacol Res 2018; 129:388-399. (7.658)
Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors. Bioorg Med Chem. 2018 Jul 23; 26(12):3308-3320. (IF 3.641)
Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α. Acta Pharmacol Sin 2018；39(3):415-424. (IF 6.15)
Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis. Front Pharmacol 2017; 8:915. (IF 5.81)
Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as noveland potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem 2017;126:1083-106. (IF 6.514)
Characterization of a near-infrared fluorescent dcpo-tagged glucose analogue for cancer cell imaging. J Photoch Photobio B 2017;166:264-71. (IF 6.252)
Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. J Exp Clin Cancer Res 2016; 35(1):183-97. (IF 11.161)
Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle 2016; 15(7):895-907. (IF 4.534)
Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker. Bioconjugate Chemistry 2016; 27(5):1267-75. (IF 4.774)
NIR fluorescent DCPO glucose analogues and their application in cancer cell imaging. RSC Adv 2016; 6(85): 81894-901. (IF 3.361)
京公网安备 11010802027423号